Journal of East China Normal University(Natural Sc ›› 2018, Vol. 2018 ›› Issue (3): 196-211.doi: 10.3969/j.issn.1000-5641.2018.03.021
Previous Articles Next Articles
CHEN Rui, FANG Yan-fen, ZHANG Xiong-wen
Received:
2017-07-06
Online:
2018-05-25
Published:
2018-05-29
CLC Number:
CHEN Rui, FANG Yan-fen, ZHANG Xiong-wen. Progress in development of small molecule inhibitors targeting indoleamine 2,3-dioxygenase[J]. Journal of East China Normal University(Natural Sc, 2018, 2018(3): 196-211.
[1] DRAKE C G, LIPSON E J, BRAHMER J R. Breathing new life into immunotherapy:Review of melanoma, lung and kidney cancer[J]. Nature Reviews Clinical oncology, 2014, 11(1):24-37. [2] PRENDERGAST G C, JAFFEE E M. Cancer Immunotherapy:Immune Suppression and Tumor Growth[M]. New York:Academic Press, 2013. [3] GERRIETS V A, RATHMELL J C. Metabolic pathways in T cell fate and function[J]. Trends in Immunology, 2012, 33(4):168-173. [4] MULLER A J, DUHADAWAY J B, DONOVER P S, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy[J]. Nature Medicine, 2005, 11(3):312-319. [5] UYTTENHOVE C, PILOTTE L, TH ATE I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase[J]. Nature Medicine, 2003, 9(10):1269-1274. [6] WICHERS M C, KOEK G H, ROBAEYS G, et al. IDO and interferon-α -induced depressive symptoms:A shift in hypothesis from tryptophan depletion to neurotoxicity[J]. Molecular Psychiatry, 2005, 10(6):538-544. [7] JONES R G, THOMPSON C B. Revving the engine:signal transduction fuels T cell activation[J]. Immunity, 2007, 27(2):173-178. [8] JENABIAN M A, EL-FAR M, VYBOH K, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection[J]. The Journal of Infectious Diseases, 2015, 212(3):355-366. [9] MUNN D H, MELLOR A L. IDO in the tumor microenvironment:Inflammation, counter-regulation, and tolerance[J]. Trends in Immunology, 2016, 37(3):193-207. [10] MUNN D H, MELLOR A L. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses[J]. Trends in Immunology, 2013, 34(3):137-143. [11] OPITZ C A, LITZENBURGER U M, SAHM F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor[J]. Nature, 2011, 478(7368):197-203. [12] PALLOTTA M T, ORABONA C, VOLPI C, et al. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells[J]. Nature Immunology, 2011, 12(9):870-8. [13] PLATTEN M, VON KNEBEL DOEBERITZ N, OEZEN I, et al. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors[J]. Frontiers in Immunology, 2014, 5:673. [14] MELLOR A L, MUNN D H. IDO expression by dendritic cells:Tolerance and tryptophan catabolism[J]. Nature Reviews Immunology, 2004, 4(10):762-774. [15] METZ R, DUHADAWAY J B, KAMASANI U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan[J]. Cancer Research, 2007, 67(15):7082-2087. [16] BALL H J, YUASA H J, AUSTIN C J, et al. Indoleamine 2, 3-dioxygenase-2:A new enzyme in the kynurenine pathway[J]. The International Journal of Biochemistry & Cell Biology, 2009, 41(3):467-471. [17] MEININGER D, ZALAMEDA L, LIU Y, et al. Purification and kinetic characterization of human indoleamine 2, 3-dioxygenases 1 and 2(IDO1 and IDO2) and discovery of selective IDO1 inhibitors[J]. Biochimica et Biophysica Acta (BBA)-proteins and Proteomics, 2011, 1814(12):1947-1954. [18] FATOKUN A A, HUNT N H, BALL H J. Indoleamine 2, 3-dioxygenase 2(IDO2) and the kynurenine pathway:Characteristics and potential roles in health and disease[J]. Amino Acids, 2013, 45(6):1319. [19] BOYLAND E, WILLIAMS D. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder[J]. Biochemical Journal, 1956, 64(3):578. [20] YOSHIDA R, IMANISHI J, OKU T, et al. Induction of pulmonary indoleamine 2, 3-dioxygenase by interferon[J]. Proceedings of the National Academy of Sciences, 1981, 78(1):129-132. [21] MUNN D H, ZHOU M, ATTWOOD J T, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism[J]. Science, 1998, 281(5380):1191-1193. [22] KANTOFF P W, HIGANO C S, SHORE N D, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. New England Journal of Medicine, 2010, 363(5):411-422. [23] ROBERT C, THOMAS L, BONDARENKO I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. New England Journal of Medicine, 2011, 364(26):2517-2526. [24] DAVILA M L, RIVIERE I, WANG X Y, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Science Translational Medicine, 2014, 6(224):224ra25. [25] JOHN L B, KERSHAW M H, DARCY P K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J]. Oncoimmunology, 2013, 2(10):e26286. [26] CURTI A, ALUIGI M, PANDOLFI S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase[J]. Leukemia, 2007, 21(2):353-355. [27] OUZOUNOVA M, LEE E, NOVAKOVIC E, et al. Abstract 1984:SOCS3 regulates IDO proteasomal degradation and inflammatory signaling in triple negative breast cancer[J]. Cancer Research, 2015, 75(15 Suppl):1984. [28] CAVIA-SAIZ M, RODR GUEZ P M, AYALA B L, et al. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer[J]. Molecular Biology Reports, 2014, 41(4):2275. [29] KIM J W, NAM K H, AHN S-H, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer[J]. Gastric Cancer, 2016, 19(1):42. [30] VELCHETI V, SCHALPER K A, CARVAJAL D E, et al. Programmed death ligand-1 expression in non-small cell lung cancer[J]. Laboratory investigation, 2014, 94(1):107-116. [31] JIA Y L, WANG H Y, WANG Y, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients[J]. International journal of cancer, 2015, 137(5):1095-1106. [32] AYUTHAYA B I N, PAVASANT P. Influence of Exogenous IL-12 on Human Periodontal Ligament Cells[J]. Interface Oral Health Science, 2017:217-228. [33] CADY S G, SONO M. 1-Methyl-dl-tryptophan, β -(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and β-[3-benzo (b) thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2, 3-dioxygenase[J]. Archives of Biochemistry and Biophysics, 1991, 291(2):326-333. [34] LÖB S, KONIGSRAINER A, ZIEKER D, et al. IDO1 and IDO2 are expressed in human tumors:Levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism[J]. Cancer Immunology, Immunotherapy, 2009, 58(1):153-157. [35] TOURINO M C, OLIVEIRA E M, BELL L P, et al. Tryptamine and dimethyltryptamine inhibit indoleamine 2, 3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells[J]. Cell biochemistry and Function, 2013, 31(5):361-364. [36] YANG S S, LI X S, HU F F, et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2, 3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice[J]. Journal of Medicinal Chemistry, 2013, 56(21):8321-8331. [37] SONO M, CADY S G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2, 3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands[J]. Biochemistry, 1989, 28(13):5392-5399. [38] KUMAR S, JALLER D, PATEL B, et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2, 3-dioxygenase[J]. Journal of Medicinal Chemistry, 2008, 51(16):4968-4977. [39] QIAN S, HE T, WANG W, et al. Discovery and preliminary structure——activity relationship of 1H-indazoles with promising indoleamine-2, 3-dioxygenase 1(IDO1) inhibition properties[J]. Bioorganic & Medicinal Chemistry, 2016, 24(23):6194-6205. [40] MEHTA R G, LIU J, CONSTANTINOU A, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage[J]. Carcinogenesis, 1995, 16(2):399-404. [41] JUNG PARK E, PEZZUTO J M. Botanicals in cancer chemoprevention[J]. Cancer and Metastasis Reviews, 2002, 21(3):231-255. [42] KUEHNL S, SCHROECKSNADEL S, TEMML V, et al. Lignans from Carthamus tinctorius suppress tryptophan breakdown via indoleamine 2, 3-dioxygenase[J]. Phytomedicine, 2013, 20(13):1190-1195. [43] RO℉RIG U F, MAJJIGAPU S R, VOGEL P, et al. Challenges in the discovery of indoleamine 2, 3-dioxygenase 1(IDO1) inhibitors[J]. Journal of Medicinal Chemistry, 2015, 58(24):9421-9437. [44] BRASTIANOS H C, VOTTERO E, PATRICK B O, et al. Exiguamine A, an indoleamine-2, 3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua[J]. Journal of the American Chemical Society, 2006, 128(50):16046-16047. [45] TUMANG J, GOMES B, WYTHES M, et al. Abstract 4863:PF-06840003:A highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors[J]. Cancer Research, 2016, 76(14 Supple):4863. [46] GYULVESZI G, FISCHER C, MIROLO M, et al. Abstract LB-085:RG70099:A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment[J]. Cancer Research, 2016, 76(14 Supplement):LB-085. [47] LIU X D, SHIN N, KOBLISH H K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity[J]. Blood, 2010, 115(17):3520-3530. [48] KOBLISH H K, HANSBURY M J, BOWMAN K J, et al. Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors[J]. Molecular Cancer Therapeutics, 2010, 9(2):489-498. [49] BEATTY G L, O'DWYER P J, CLARK J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies[J]. Journal of Clinical Oncology, 2013, 31(15):1904-1911. [50] GIBNEY G T, HAMID O, GANGADHAR T C, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma[J]. Journal of Clinical Oncology, 2014. [51] SMITH D C, GAJEWSKI T, HAMID O, et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma:Preliminary phase I/Ⅱ results of ECHO-202/KEYNOTE-037[J]. Annals of Oncology, 2016, 27(Suppl 6):vi379-vi400. [52] GANGADHAR T, HAMID O, SMITH D, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors:Updated phase 1 results from ECHO-202/KEYNOTE-037[J]. Annals of Oncology, 2016, 27(Suppl 6):1110PD. [53] KOMROKJI R S, WEI S, MAILLOUX A W, et al. A phase Ⅱ study to determine the safety and efficacy of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes[J]. Blood, 2014, 124:4653-4653. [54] SOLIMAN H H, JACKSON E, NEUGER T, et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors[J]. Oncotarget, 2014, 5(18):8136. [55] SOLIMAN H, ANTONIA S, SULLIVAN D, et al. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2, 3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)[J]. Journal of Clinical Oncology, 2009, 27(15 supplment):3004. [56] SOLIMAN H H, MINTON S E, HAN H S, et al. A Phase I study of indoximod in patients with advanced malignancies[J]. Oncotarget, 2016, 7(16):22928. [57] JACKSON E, MINTON S E, ISMAIL-KHAN R, et al. A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors[J]. Journal of Clinical Oncology, 2012. [58] ZAKHARIA Y, MCWILLIAMS R, SHAHEEN M, et al. Abstract CT117:Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma[J]. Cancer Research, 2017, 77(13 Supplement):CT117. [59] MAUTINO M R, JAIPURI F A, WALDO J, et al. Abstract 491:NLG919, a novel indoleamine-2, 3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy[J]. Cancer Research, 2013, 73(8 Supple):491. [60] KHLEIF S, MUNN D, NYAK-KAPOOR A, et al. First-in-human phase 1 study of the novel indoleamine-2, 3-dioxygenase (IDO) inhibitor NLG-919[J]. Journal of Clinical Oncology, 2014. [61] NAYAK A, HAO Z, SADEK R, et al. 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors[J]. European Journal of Cancer, 2015, 51:S69. [62] SIU L L, GELMON K, CHU Q, et al. Abstract CT116:BMS-986205, an optimized indoleamine 2, 3-dioxygenase 1(IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial[C]//Proceedings:AACR Annual Meeting. Washington, DC:American Association for Cancer Research, 2017(4):1-5. [63] BALACHANDRAN V P, CAVNAR M J, ZENG S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido[J]. Nature medicine, 2011, 17(9):1094-1100. |
[1] | Mingli ZHANG, Yichong CUI, Liangjun DA. Distribution and causes of ruderal communities in different urban habitats of Hangzhou [J]. Journal of East China Normal University(Natural Science), 2021, 2021(2): 120-131. |
[2] | Yuanyuan LI, Kankan SHANG, Xijin ZHANG, Kun SONG. Vessel characteristics and the density-size relationship of woody plantsat the Shanghai Chenshan Botanical Garden [J]. Journal of East China Normal University(Natural Science), 2021, 2021(2): 142-150. |
[3] | ZHU Xiao-jing, YUAN Lin, ZHAO Zhi-yuan, ZHANG Li-quan, LI Wei, WEI Wei, PAN Jia-lin, CHEN Ya-hui. The influence of environmental factors on the settlement of Spartina alterniflora on tidal flats [J]. Journal of East China Normal University(Natural Sc, 2019, 2019(6): 140-152. |
[4] | YIN Qian, WANG Hong-jiang, LIU Xing-jian. An investigation of the invasive plants in Nanjing Botanical Garden Memorial Sun Yat-Sen [J]. Journal of East China Normal University(Natural Sc, 2019, 2019(2): 128-134,163. |
[5] | BAI Mei, WU Hui. Characteristics of sea surface temperature in the Changjiang Estuary and adjacent waters based on a Self-Organizing Map [J]. Journal of East China Normal University(Natural Sc, 2018, 2018(4): 184-194. |
[6] | LIU Yan, Winira ILGHAR, Gulnigar AYSIRAHUN, Mamtimin SULAYMAN. Additional information on Sphagnaceae species in Xinjiang [J]. Journal of East China Normal University(Natural Sc, 2018, 2018(3): 190-195,211. |
[7] | WANG Jiu-zhong, WU Ming-quan. Spatio-temporal analysis about the primary productivity of Mentougou District in Beijing from 2003 to 2014 [J]. Journal of East China Normal University(Natural Sc, 2018, 2018(1): 163-170. |
[8] | ZHANG Shen-Yu, ZHU Jian-Rong. Observation and analyses of transport and diffusion of warm discharge water from the power plants near Shidongkou in the Changjiang Estuary [J]. Journal of East China Normal University(Natural Sc, 2016, 2016(2): 101-111. |
[9] | MA Li, CHEN Yuan, LI Qi. Typological analysis of “Prototype” of the traditional waterfront architecture [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(6): 170-178. |
[10] | . Privacypreserving range query processing in wireless sensor networks [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(5): 1-13. |
[11] | ZHENG Miao,WANG Bin,YANG Xiao-chun. Privacy preservation approach for location based service on road network [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(5): 116-127. |
[12] | LIU Shushu,LIU An,LIU Guanfeng,LI Zhixu,ZHAO Lei,ZHENG Kai. A privacy preserving framework for efficient computation of trajectory similarity [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(5): 154-161. |
[13] | ZHANG Chen-dong,GUO Jin-wei,LIU Bo-zhong,CHU Jia-jia,ZHOU Min-qi,QIAN Wei-ning. High availability implementation based on Raft [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(5): 172-. |
[14] | ZHANG Yan-Yan, WEI Jin-Bao, HUANG Min-Sheng, CAO Cheng-Jin, HE Yan. Effects of environment factors on the growth of phytoplankton in Dishui Lake [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(2): 48-57. |
[15] | DUAN Xiu-Wen, CAI Bei-Ming, CHEN Xiao-Shuang, CUI Yi-Chong, DA Liang-Jun-. Variation of leaf nitrogen and phosphorus of annual weeds along urban rural gradient and their relationships with soil fertility [J]. Journal of East China Normal University(Natural Sc, 2015, 2015(2): 133-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||